ULURU Inc. Announces The Launch Of Altrazeal® 0.75 Gram Blister
Pack In The United States
ADDISON, Texas, Jan. 14, 2013 /PRNewswire/ -- ULURU
Inc. (OTCQB: ULUR) announced today the availability in the U.S.
market of Altrazeal® in an innovative 0.75 gram blister
pack.
The development of this innovative packaging system was in
response to requests from wound care practitioners. This packaging
configuration overcomes the concerns expressed by users, including
excessive waste of product, inability to see the product during
application and unit cost for the treatment of small chronic
wounds.
In addition to the new 0.75 gram blister pack the Company will
continue to offer Altrazeal® in 2 gram and 5 gram foil
pouches. The launch of the 0.75 gram blister pack is designed
to:
- Provide a more appropriate quantity for the treatment of
chronic wounds
- Provide a pack that incorporates an applicator to further
improve ease of use
- Enable the practitioner to more easily dispense the required
amount of product as the powder is visible in the transparent
blister pack
- Have a price point that is consistent with the hospital and
wound care center reimbursement structure
- Have a price point that enables greater penetration into the
nursing home and long-term acute care facilities
Commenting on the launch of Altrazeal® 0.75 gram
blister pack in the U.S., Kerry P.
Gray, President and CEO of ULURU Inc., stated, "In the near
term we see this as the largest selling pack size as the volume of
product and the associated treatment cost is more appropriate for
smaller chronic wounds including diabetic foot ulcers and a high
percentage of venous leg ulcers. Currently, the cost of the
dressing used in a wound care center is covered under a procedural
code, consequently, these facilities are very cost conscious when
choosing the wound dressing to be used. Likewise, with nursing
homes and long term care facilities, as the cost of wound dressings
are the responsibility of these centers unit, acquisition cost is
the primary focus. The blister pack concept is a significant
advancement in the delivery of Altrazeal® to the wound
and provides a product enhancement requested by wound care
professionals."
Altrazeal® is an advanced scientifically engineered
material that is unique in the field of advanced wound care
dressings in terms of properties and performance. It incorporates
the features and benefits of the desired "ideal" wound dressing.
Altrazeal® has demonstrated potential clinical and
economic advantages in a number of chronic and acute wounds
including diabetic foot ulcers, venous leg ulcers, pressure ulcers
and geriatric wounds.
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on
the development of a portfolio of wound management and oral care
products to provide patients and consumers improved clinical
outcomes through controlled delivery utilizing its innovative
Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery
system. For further information about ULURU Inc., please
visit our website at www.ULURUInc.com. For further
information about Altrazeal®, please visit
www.Altrazeal.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended, including but not limited to statements
made relating to the improved pack design of
Altrazeal®, advantages of the blister pack, and
the 0.75 gram pack becoming the largest volume pack size. These
statements are subject to numerous risks and uncertainties,
including but not limited to ULURU's lack of profitability, the
need for additional capital to operate its business, and to risk
factors detailed in the Company's Annual Report on Form 10-K for
the year ended December 31, 2011, and
other reports filed by us with the Securities and Exchange
Commission.
Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145
SOURCE ULURU Inc.